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Background: Increased low-density lipoprotein cholesterol (LDL) concentration is associated with increased risk of
coronary heart disease (CHD) but a substantial risk of cardiovascular disease often remains after LDL concentrations
have been treated to target. Apolipoprotein B (apo B) is the major apolipoprotein contained within atherogenic
lipoproteins such as LDL, and apo B is a more reliable indicator of cardiovascular risk than LDL concentration.
Aim and methods: Our aim was to develop a formula for calculating apo B using lipid biochemistry
measurements that are commonly available in clinical practice. We examined the clinical and laboratory data from
73,047 Koreans who underwent a medical health check that included apolipoprotein B concentration. The study
sample was randomly divided into a training set for prediction model building and a validation set of equal size.
Multivariable linear regression analysis was used to develop a prediction model equation for estimating apo B and
to validate the developed model.
Results: The best results for estimating apo B were derived from an equation utilising LDL and triglyceride (TG)
concentrations [ApoB =−33.12 + 0.675*LDL + 11.95*ln(tg)]. This equation predicted the apo B result with a
concordance correlation coefficient (CCC and 95%CIs) = 0.936 (0.935,0.937)).
Conclusion: Our equation for predicting apo B concentrations from routine analytical lipid biochemistry provides a
simple method for obtaining precise information about an important cardiovascular risk marker.
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The association between increased concentrations of
low-density lipoprotein cholesterol (LDL) and increased
rates of premature coronary heart disease has been
clearly demonstrated [1-8]. Current recommendations
for the management of dyslipidemia are largely based on
treatments to decrease LDL concentration [5,9-14].
However, a significant residual risk of cardiovascular dis-
ease (CVD) often remains after low-density lipoprotein
cholesterol levels have been treated to target [15-20].* Correspondence: kcmd.sung@samsung.com
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reproduction in any medium, provided the orApolipoprotein B100 (apoB) is the structural protein for
atherogenic lipoproteins and facilitates the transporting of
lipid from the liver to peripheral tissues [15,21-23]. A sin-
gle apo B100 molecule is present in all major atherogenic
particles derived from the liver (very low density lipopro-
tein (VLDL), intermediate density lipoprotein (IDL) and
LDL). Consequently, measurement of apoB100 provides
direct information as to the number of circulating athero-
genic particles [23]. Apo B100 concentration is a better
measure of LDL particle number concentration and is a
more reliable indicator of risk than LDL concentration
[22,24,25]. Thus, addition of apo B100 concentration to
the routine lipid profile could improve identification of
patients at risk of CVD and could improve management
of those patients who are receiving lipid lowering therapy. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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prediction in people with diabetes or metabolic syndrome
[24,32] and Apo B100 may provide a better assessment of
on-treatment residual risk (than LDL) providing support
for the notion that addition of apo B100 measurement to
the routine lipid panel would improve patient manage-
ment [26,31].
Apo B100 can be measured by commercial immuno-
assay [33] but assays are time-consuming and costly
[34]. Although an algorithm for estimating apo B100
has previously been developed by Hermans et al. [23],
this algorithm was developed in 45 people with dia-
betes from a Western population. Thus, the aim of our
study was to develop an algorithm for estimating the
apo B100 concentration from easily measured para-
meters; e.g. age, body mass index (BMI), low desntiy
lipoprotein cholesterol (LDLc), high density lipopro-
tein cholesterol (HDLc), triglyceride (TG) and total
cholesterol (TC) concentrations.Methods
A total of 73,047 apparently healthy subjects were
recruited for the study. The mean age was 41.73 ± 8.4
years, [n = 44,118 men (41.9 ± 8.1-years) and n= 28,929
women (41.4 ± 8.7-years)]. Subjects participated in a rou-
tine health check-up program that was held at the
Health Promotion Center of Kangbuk Samsung Hospital,
Sungkyunkwan University School of Medicine, Seoul,
Korea in 2008. The medical health checkup program
was developed to improve the health of employees. Most
subjects were employees, or family members, from vari-
ous industrial companies across the country. The cost of
medical examinations was predominantly paid for by the
employers, and most subjects underwent a health check
annually or biannually. The study protocol conformed to
the ethical guidelines of the 1975 Declaration of Helsinki
as reflected by a priori approval from our institution’s
Human Research Committee.
The health check consisted of a full medical history
and comprehensive blood test evaluation. Participants’Table 1 Characteristics of the whole cohort, and the model b
Total (n = 73047)
Age (years) 41.73 ± 8.38
Gender (M/F) 44118/28929
Total cholesterol (mg/dL) 195.17 ± 33.79
TG (mg/dL) 127.55 ± 86.80
HDLc (mg/dL) 55.20 ± 12.73
LDLc (mg/dL) 110.63 ± 29.43
ApoB100 (mg/dL) 97.52 ± 23.97
BMI (kg/m2) 23.63 ± 3.12
Data are expressed as mean ± SD or median [interquartile range], unless indicated o
density lipoprotein cholesterol, Apo B100: apolipoprotein B100, BMI: body mass indheight and weight were measured barefoot and in light
clothing. BMI was calculated as weight in kilograms
divided by height in meters squared. Laboratory exami-
nations were obtained after an overnight fast. An enzym-
atic calorimetric test was used to measure TC and TG
concentrations. The selective inhibition method was
used to measure HDLc, and a homogeneous enzymatic
calorimetric method was used to measure the concentra-
tion of LDLc (Advia 1650 Autoanalyzer, Bayer Diagnostics,
Leverkusen, Germany). Apo B100 and apoA1 concentra-
tions were determined by rate nephelometry (IMMAGE
system; Beckman Coulter).
Descriptive statistics for continuous variables are pre-
sented as means, standard deviations (SDs), medians and
inter-quartile ranges (Q1, Q3). Categorical variable are
presented as proportions (percentages).
The study sample was randomly divided into a training
set for prediction model building and a validation set of
equal size. Multivariable linear regression analysis was
used to develop a prediction model equation and to val-
idate the developed model. Natural log transformation
was used to normalize the distribution of HDLc, TG, age
and BMI. Analysis of residuals was used to check
assumptions for multivariable linear regression model-
ing. The accuracy of the prediction model equation was
evaluated using concordance correlation coefficient
(CCC) analysis (Lin (1989)) that allowed comparison
between prediction modeling results and the direct
biochemical measurement of apo B100. In all tests,
p-values < 0.05 were considered significant. Statistical
analyses were performed using SAS 9.1.3 (SAS Institute
Inc, Cary, NC) and R 2.13.2 (Vienna, Austria).
We conducted subgroup analyses by sex, glucose (7.0
mmol/l or 126 mg/dl), BMI (25kg/m2) and apoB quar-
tile, in order to examine whether the derived equation
was appropriate for specific subpopulation.Results
The characteristics of subjects in the model building
subsample and the validation subsample were similaruilding and validation subsets
Model building (n = 36523) Validation set (n = 36524)
41.7 ± 8.4 41.7 ± 8.4
22034/14489 22084/14440
195.12 ± 33.89 195.22 ± 33.70
127.40 ± 86.25104(73,156) 127.70 ± 87.34105 (73,156)
55.19 ± 12.73 55.20 ± 12.74
110.62 ± 29.48 110.64 ± 29.37
97.53 ± 24.04 97.50 ± 23.0
23.64 ± 3.12 23.63 ± 3.11
therwise. TG: triglyceride, HDLc: High density lipoprotein cholesterol, LDLc: low
ex.
Table 2 Models for predicting apoB100 concentration
Prediction equation P-value R-square CCC[95% CI]
1. LDLc ApoB100= 16.177816+ 0.735235*LDLc <.0001 81.1% 0.90 [0.890-0.898]
2. LDLc, age ApoB100=−24.77 + 0.72*LDLc + 11.43*ln(age) <.0001 81.9% 0.90 [0.899-0.903]
3. LDLc, BMI ApoB100=−49.13 + 0.70*LDLc + 21.81*ln(BMI) <.0001 82.4% 0.90 [0.902-0.905]
4. LDLc, BMI, age ApoB100=−78.91 + 0.696*LDLc+ 9.81*ln(나이) + 19.98*ln(BMI) <.0001 83.0% 0.91 [0.905-0.909]
5. LDLc, TG ApoB100=−33.12 + 0.675*LDLc+ 11.95*ln(tg) <.0001 88.0% 0.94 [0.935-0.937]
6. LDLc, TG, age ApoB100=−59.40 + 0.67*LDLc + 11.63*ln(tg) + 7.68*ln(age) <.0001 88.3% 0.94 [0.937-0.939]
7. LDLc, TG, BMI ApoB100=−35.99 + 0.67*LDLc + 11.84*ln(tg) + 1.11*ln(BMI) <.0001 88.0% 0.94 [0.935-0.937]
8. LDLc, TG, age, BMI ApoB100=−59.53 + 0.67*LDLc + 11.62*ln(tg) + 7.68*ln(age) + 0.05*ln(BMI) <.0001 88.3% 0.94 [0.937-0.940]
!Multiple linear regression analyses were used to develop a prediction equation.
!CCC indicates concordance correlation coefficient.
!CI indicates confidence interval.
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Subjects with high glucose (>7.0 mmol/l, or >126 mg/dl)
were only 932(2.6% of total subjects).Variables entered
into the prediction equation were LDLc, HDLc, TG, age
and BMI. LDLc, TC, ln(TG), ln(BMI) and ln(age) were
each associated with apo B100, whereas apo B was not
associated with HDLc.
We developed equations for predicting apo B100 from
the results of multivariable regression modeling and
compared apo B100 concentrations obtained by direct
measurement with apo B100 estimates from various pre-
diction model formulae (Table 2). An equation including
LDLc, ln(TG), ln(age) and ln(BMI), produced the highest
R2 results and the highest CCC. However, an equation
that included LDLc, ln(TG) and ln(Age) produced a
higher F –statistic than one that also included ln(BMI).
However, since BMI added little to an equation that
included just LDLc, and TG, we tested the equation
‘ApoB100 =−33.12 + 0.675*LDL+ 11.95*ln(tg)’ in the val-
idation data-set. In this data-set the CCC was 0.936(95%
CI(0.935-0.937)).
We also estimated apo B100 using published predic-
tion equations [23,33] and compared predicted valuesEquation 1 Equa
a b
Figure 1 Scatter plot of estimated results by each equation and obsefrom these equations with concentrations obtained from
direct biochemical measurements. Figures 1a, b and c
show the scatter plots for the relationships between pre-
dicted and observed apo B measurements for the devel-
oped equation, and for the two published equations. We
compared CCC values for our equation ApoB100 =
−33.12 + 0.675*LDL+ 11.95*ln(tg) with the two pub-
lished equations (Table 3). We also compared the three
equations stratified by sex, glucose (7.0mmol/l or 126
mg/dl) and BMI (≥25kg/m2) thresholds, and apo B100
quartiles (Table 4).
The CCC for obese individuals with a BMI > 28kg/m2
was 0.914(95% CI(0.908-0.920)). We also tested the for-
mula also in subjects with an atherogenic lipid profile,
namely in those with a TG> 150 mg/dl +HDLc < 40/<50
mg/dl. In individuals with TG> 150 & HDLc < 50 (fe-
male), the CCC was 0.923(95% CI(0.917-0.929)). In indi-
viduals with TG> 150 & HDcL < 40 (male), the CCC was
0.932(95% CI(0.924-0.939)). We also calculated the per-
formance of the proposed equation using estimated
LDLc from Friedewald’s equation. The CCCs are 0.920
(95% CI(0.919-0.922)) in the training data-set and 0.922
(95% CI(0.920-0.924)) in the validation data-set.tion 2 Equation 3
c
rved results.
Table 3 CCC values for the developed equation* and published equations
CCC [95% CI]
Equation1: ApoB100=−33.12 + 0.675*LDLc+ 11.95*ln(tg) 0.94 [0.93 0.94]
Equation 2: ApoB100= 20.67944 + 0.551614*non HDLc, where non HDLc = total C-HDLc 0.912 [0.91 0.91]
Equation 3: ApoB100= 6.3 + 0.65*non HDLc, where non HDLc = total C-HDLc 0.93 [0.93 0.94]
Equation2: ApoB100 = 20.67944 + 0.551614*non HDLc, where non HDLc = total C-HDLc.
Equation 2 from Krishnaji Kulkarni (29).
Equation3: ApoB = 6.3 + 0.65*non HDLc, where non HDLc = total C-HDLc.
Equation 3 from Hermans et al(20).
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Measurement of apo B100 concentrations helps cardio-
vascular risk prediction but unfortunately to date apo
B100 assays are often not available because they are con-
sidered expensive and time consuming. Consequently, apo
B100 measurements are not readily available to clinicians.
From a very large cohort of subjects that are representa-
tive of a general Asian population, we have developed a
very simple algorithm for estimating apo B100 concentra-
tion that utilizes only LDLc and fasting triglyceride con-
centrations. Although more complex equations fitted the
data slightly better for predicting apo B100; the very sim-
ple algorithm did not compromise precision, compared
with the more complex equations. We have also shown
that the simple algorithm is valid in important sub groups
of people that included obese subjects, subjects with
increased plasma glucose concentrations and subjects
with an atherogenic lipid profile. The derived formula is
also appropriate if LDLc is estimated from Friedewald’s
equation.
The CCCs for apoB100 in Q2 and Q3 were lower than
for the other two quartiles. To evaluate the reason for
the lower CCC results in Q2 and Q3, we compared the
characteristics of the relationship between apoB100 and
LDLc in each quartile. In the total data set, the relation-
ship between apoB100 and LDLc showed a clear positive
linear relationship, whereas in Q2 and Q3, the relation-
ship was not linear In Q2 and Q3 the data points wereTable 4 Comparative CCC results for the developed equation
and BMI thresholds and apo B quartile
Male Female glucose >126mg/d
CCC [95% CI] CCC [95% CI] CCC [95% CI]
Equation1 0.92 [0.92 0.93] 0.94 [0.93 0.94] 0.91 [0.90 0.9
Equation2 0.90 [0.90 0.90] 0.91 [0.91 0.91] 0.84 [0.82 0.8
Equation3 0.92 [0.92 0.92] 0.94 [0.94 0.94] 0.84 [0.82 0.8
Apolipoprotein
Q1(<80.24) Q2(80.24< Q2<
CCC [95% CI] CCC [95
Equation1 0.71 0.70 0.72 0.25 0.23
Equation2 0.51 0.50 0.51 0.22 0.20
Equation3 0.66 0.65 0.67 0.23 0.21
N=36,524 participants who were randomly divided into a validation set.concentrated around the middle of the distribution, ra-
ther than being spread evenly along the regression line.
Consequently, the scatter of data in these middle two
quartiles did not fit the regression line as well as in Q1
and Q4. Thus, this finding may limit the usefulness of
our formula in these middle two quartiles. However, our
equation was developed for the whole population and
not just for the subjects in the 2nd and 3rd quartile. We
reason that it is more important to fit the formula to the
whole population and not to a specific subgroup within
that population.
Conclusion
In conclusion, we have developed an algorithm in a large
Asian population to derive an estimate of apoB100 con-
cetnrations that utilizes only measurement of LDLc and
triglyceride concentrations from a fasting plasma sam-
ple. We are unable to comment as to whether the algo-
rithm is valid in a Western population.
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